Valuation: Cytosorbents Corporation

Market Cap 22.77M 19.74M 18.5M 16.87M 31.74M 2.17B 32.25M 218M 85.04M 1.09B 85.48M 83.63M 3.63B P/E 2026 *
-1.65x
P/E 2027 * -
Enterprise Value 22.77M 19.74M 18.5M 16.87M 31.74M 2.17B 32.25M 218M 85.04M 1.09B 85.48M 83.63M 3.63B EV / Sales 2026 *
0.57x
EV / Sales 2027 * 0.48x
Free-Float
84.28%
Yield 2026 *
-
Yield 2027 * -
1 day+4.61%
1 week+6.89%
Current month+6.62%
1 month-0.95%
3 months-28.98%
6 months-39.88%
Current year-39.80%
1 week 0.36
Extreme 0.36
0.4
1 month 0.35
Extreme 0.35
0.4
Current year 0.35
Extreme 0.35
0.84
1 year 0.35
Extreme 0.35
1.19
3 years 0.35
Extreme 0.35
2.95
5 years 0.35
Extreme 0.35
9.8
10 years 0.35
Extreme 0.35
14.95
Manager TitleAgeSince
Chief Executive Officer 55 2008-07-23
Director of Finance/CFO 62 2024-08-13
President 68 2020-04-27
Director TitleAgeSince
Director/Board Member 77 2011-07-24
Director/Board Member 55 2008-12-31
Director/Board Member 65 2014-11-12
Date Insider Type Main position Quantity % Market Cap.
11/18/25 Free

Chief Executive Officer

100,000 0.1593%
8/8/25 Free

Chief Financial Officer

161,500 0.2579%
8/8/25 Free

Chief Executive Officer

242,000 0.3865%
Change 5-day change 1-year change 3-year change Capi.($)
+6.21%+6.89%-66.25%-86.69% 22.77M
-0.35%-0.30%+22.10%+9.60% 220B
-0.08%-0.60%-3.18%-20.86% 143B
-0.38%+5.48%-16.25%+30.97% 142B
+1.00%+5.51%-50.05%+1.35% 74.91B
-0.36%+2.62%+17.77%+14.33% 53.35B
+0.68%-0.53%-15.99%-16.58% 50.13B
-0.56%+1.63%+24.80%+17.13% 42.16B
-0.69%+0.96%+39.94%+42.44% 40.63B
-0.33%+2.56%-0.07%+2.51% 33.33B
Average +0.41%+2.63%-4.72%-0.58% 80B
Weighted average by Cap. -0.10%+3.84%+1.46%+7.60%

Financials

2026 *2027 *
Net sales 39.61M 34.34M 32.19M 29.35M 55.22M 3.78B 56.11M 379M 148M 1.89B 149M 146M 6.31B 47.12M 40.85M 38.29M 34.91M 65.69M 4.5B 66.75M 451M 176M 2.25B 177M 173M 7.51B
Net income -13.95M -12.09M -11.33M -10.33M -19.45M -1.33B -19.76M -133M -52.1M -666M -52.37M -51.23M -2.22B -130K -113K -106K -96.32K -181K -12.41M -184K -1.24M -486K -6.21M -488K -477K -20.72M
Net Debt - -
Logo Cytosorbents Corporation
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Employees
129
Date Price Change Volume
26-08-14 $0.3848 +6.21% 13,796
26-08-13 $0.3623 -2.08% 41,887
26-08-12 $0.3700 +2.78% 104,864
26-08-11 $0.3600 -0.55% 40,754
26-08-10 $0.3620 +0.56% 74,586
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.3623USD
Average target price
5.000USD
Spread / Average Target
+1,280.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CTSO Stock